Publicación:
The GnRH Agonist Triptorelin Causes Reversible, Focal, and Partial Testicular Atrophy in Rats, Maintaining Sperm Production

dc.contributor.authorMarcos, Alberto
dc.contributor.authorRodríguez Del Cerro, María Cruz
dc.contributor.authorFernández, Rosa María
dc.contributor.authorPásaro, Eduardo
dc.contributor.authorArias-Ramos, Nuria
dc.contributor.authorLópez-Larrubia, Pilar
dc.contributor.authorGonzález-Peramato, Pilar
dc.contributor.authorGuillamón Fernández, Antonio
dc.contributor.authorDe Miguel, Maria P.
dc.date.accessioned2025-10-31T11:55:43Z
dc.date.available2025-10-31T11:55:43Z
dc.date.issued2025-07-08
dc.description.abstractWe aim to provide a translational model to investigate the reproductive consequences of pubertal delay using the GnRH agonist triptorelin in transgender girls, tested in particular on testicular maturation in peripubertal rats. A total of 30 Sprague Dawley rats were utilized, with 10 subjects assigned to each of three groups from day P30 postpartum (prepubertal) until day P95 (postpubertal), mimicking treatment timing in patients. Rats received triptorelin at three time points (P30, P50, and P71), or only at P30 and P50. Control rats were injected with vehicle. Plasma testosterone levels were determined using MRM analysis. Testes and epididymides were examined histologically. There were significantly lower testosterone levels at postnatal day 48 in treated rats, indicating delayed puberty, with further reductions by day 69. By day 93, testosterone levels had recovered in rats given vehicle at P71 but remained low in the triptorelin-continuous group, suggesting the reversibility of the treatment. Treated rats had smaller testes; however, the majority of the testicular parenchyma was unaffected, with most seminiferous tubules displaying complete spermatogenesis. However, focal atrophic changes were observed in 1–30% of the parenchyma. One-third of the short-term group and half of the long-term group were classified as atrophic. Despite these changes, all treated rats had mature sperm in the epididymis, ensuring their fertility. In conclusion, triptorelin treatment promotes a decline in testosterone levels accompanied by discrete atrophy of the seminiferous tubules, which is partially reversible and compatible with sperm production and fertility preservation. Triptorelin could be an appropriate treatment prior to estrogen therapy for patients seeking gender transition. en
dc.description.versionversión publicada
dc.identifier.citationMarcos, A.; Rodríguez del Cerro, M.C.; Fernández, R.M.; Pásaro, E.; Arias-Ramos, N.; López-Larrubia, P.; González-Peramato, P.; Guillamon, A.; De Miguel, M.P. The GnRH Agonist Triptorelin Causes Reversible, Focal, and Partial Testicular Atrophy in Rats, Maintaining Sperm Production. Int. J. Mol. Sci. 2025, 26, 6566. https://doi.org/10.3390/ijms26146566
dc.identifier.doihttps://doi.org/10.3390/ijms26146566
dc.identifier.issn1422-0067
dc.identifier.urihttps://hdl.handle.net/20.500.14468/30716
dc.journal.issue6566
dc.journal.titleInternational Journal of Molecular Sciences
dc.journal.volume26
dc.language.isoen
dc.publisherMDPI
dc.relation.centerFacultad de Psicología
dc.relation.departmentPsicobiología
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.es
dc.subject3205.02 Endocrinología
dc.subject.keywordsGnRH agonistsen
dc.subject.keywordstriptorelinen
dc.subject.keywordsrat testesen
dc.subject.keywordsfertilityen
dc.subject.keywordstransgender girlsen
dc.titleThe GnRH Agonist Triptorelin Causes Reversible, Focal, and Partial Testicular Atrophy in Rats, Maintaining Sperm Productiones
dc.typeartículoes
dc.typejournal articleen
dspace.entity.typePublication
relation.isAuthorOfPublication41fb37a1-b419-4bc7-9156-9f17e4bb6ca2
relation.isAuthorOfPublicationfe1fe829-effa-4eee-8cde-8b382270a8f4
relation.isAuthorOfPublication.latestForDiscovery41fb37a1-b419-4bc7-9156-9f17e4bb6ca2
Archivos
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
3.62 KB
Formato:
Item-specific license agreed to upon submission
Descripción: